Abstract: Background : Most patients with NSCLC are diagnosed in advanced stage. Several investigators evaluated the possibility to modulate the immune system for treating lung cancer. PD-L1 expression on tumour cells leads to the inhibition of immune responses against cancer. The aim of this study is to differentiate expression PD-L1 in lung adenocarcinoma and lung squamous cell carcinoma.